The overall efficacy of chimeric antigen receptor modified T cells (CARTs) remain limited in
solid tumors despite intensive studies that aim at targeting multiple antigens, enhancing …

Chimeric antigen receptor (CAR) T cells therapy has emerged as a significant breakthrough
in adoptive immunotherapy for hematological malignancies with FDA approval. However …

Simple Summary The ultimate goal of T cell-engaging immunotherapy is to endorse the
activity of a person's own cytotoxic T cells in the tumor microenvironment, finally destroying …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in
individuals with hematological malignancies, but its success has been hindered by barriers …

FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several
decades of technology development and interrogation of the properties of these gene …

Recent studies have highlighted the successes of chimeric antigen receptor‐modified T‐
(CART‐) cell‐based therapy for B‐cell malignancies, and early phase clinical trials have …

Chimeric antigen receptor T cells (CAR-T) therapy has shown great potential in tumor
treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic …

Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that
is considered a 'living'and self-replicating drug to treat cancer, sometimes resulting in a …

Chimeric antigen receptors are genetically encoded artificial fusion molecules that can re-
program the specificity of peripheral blood polyclonal T-cells against a selected cell surface …

Chimeric antigen receptor (CAR) T-cell immunotherapy refers to an adoptive
immunotherapy that has rapidly developed in recent years. It is a novel type of treatment that …